Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Interferon treatment in patients with hypereosinophilia

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. The α7 nicotinic acetylcholine receptor complex: one, two or multiple drug targets?

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Interferon alpha for treatment of chronic myeloid leukemia

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Interferon-α treatment in systemic mastocytosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Interferon-alpha in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. Status and perspectives

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Rational targeting of the urokinase receptor (uPAR): development of antagonists and non-invasive imaging probes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Abnormal eosinophil count at CLL diagnosis correlates with shorter treatment free survival

    Publikation: Bidrag til tidsskriftLetterForskningpeer review

  2. Ruxolitinib and interferon-α2 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Association of the blood eosinophil count with end-organ symptoms

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Hydrochloric acid prolongs the lifetime of central venous catheters in haematologic patients with bacteraemia

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer
Most of the primary conditions with eosinophilia have now been characterized by clonality in 2008 by the WHO classification, which thereby provide a basis for separation of patients who may benefit a targeted therapy, i.e. by tyrosine kinase inhibition--and who may not. Treatment with interferon-α was introduced some 20 years ago and still has a role in subsets of patients, which is evident from this review of casuistic reports of treatment. However, controlled, randomized, prospective, clinical trials in multi-center studies are needed to clarify dosages, monitoring, prognosis and perhaps combination therapies with interferon-α, i.e. antibodies or other immune suppressants, in the rare patients with primary eosinophilia.
OriginalsprogEngelsk
TidsskriftCurrent Drug Targets
Vol/bind12
Udgave nummer3
Sider (fra-til)429-32
Antal sider4
ISSN1389-4501
StatusUdgivet - 2011

ID: 33237747